Liebchen, Uwe
Scharf, Christina
Zoller, Michael
Weinelt, Ferdinand
Kloft, Charlotte http://orcid.org/0000-0001-9344-8514
Michelet, Robin
Schroeder, Ines
Paal, Michael
Vogeser, Michael
Irlbeck, Michael
Briegel, Josef
Zander, Johannes
Huisinga, Wilhelm
,
Funding for this research was provided by:
Medizinischen Fakultät, Ludwig-Maximilians-Universität München
Freie Universität Berlin
Article History
Accepted: 16 July 2021
First Online: 14 September 2021
Declarations
:
: CK and WH report grants from an industry consortium (AbbVie Deutschland GmbH & Co. KG, AstraZeneca, Boehringer Ingelheim Pharma GmbH & Co. KG, Grünenthal GmbH, F. Hoffmann-La Roche Ltd, Merck KGaA and SANOFI) for the PharMetrX PhD program. CK reports grants from the Innovative Medicines Initiative-Joint Undertaking ("DDMoRe”), Diurnal Ltd., the Federal Ministry of Education and Research within the Joint Programming Initiative on Antimicrobial Resistance Initiative (JPIAMR) and the European Commission within the Horizon 2020 framework program (“FAIR”), all outside the submitted work.
: This study was performed in line with the principles of the Declaration of Helsinki. Ethical approval and consent were obtained from the Institutional Review Board of the Medical Faculty of the Ludwig-Maximilians-Universität München (Munich, Germany) [registration No. 428-12 and 18-578].